Denali Therapeutics Inc

XNAS:DNLI

20.57

-0.13 (-0.63%)

6:51:35 PM EDT: $20.50 -0.07 (-0.34%)

Market Cap (Intraday)	3.24B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$17.42 Million
Adjusted EPS	-$0.66

See more estimates

10-Day MA	$20.78
50-Day MA	$19.79
200-Day MA	$16.48

See more pivots

Denali Therapeutics Inc Stock, XNAS:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080

United States of America

Phone: +1.615.866.8548

Number of Employees: 422

http://www.denalitherapeutics.com

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.